viewFaron Pharmaceuticals Ltd

Faron Pharmaceuticals garners some encouragement from phase III data; still searching for answers to key questions

It has discovered that a sub-group of patients with higher levels of certain bio-markers showed a reduced mortality rate and increased ventilator-free days

words clinical trial on a folder
Faron is trying to understand and explain a number of anomalies in the results

Faron Pharmaceuticals Ltd (LON:FARN) has made some important observations while assessing the data from its unsuccessful phase III trial of Traumakine for acute respiratory distress syndrome (ARDS).  

It has discovered that a sub-group of patients with higher levels of certain bio-markers (CD73 serum and MxA activation) showed a reduced mortality rate and increased ventilator-free days.

The results from this smaller cohort of 48 people mirrored those seen in the company's positive phase II study.

CLICK HERE: For the update in full 

But, as chief exeutive Dr Markku Jalkanen pointed out, while the feedback was encouraging it still did not explain many of the other results observed from the pivotal clinical assessment of the treatment.

Faron's team is still trying to understand why Traumakine activity was variable in the INTEREST trial compared to previous studies and why the mortality was so low in the group receiving the dummy placebo drug.

"This analysis will continue and we will keep our shareholders and the market informed with progress in due course," Jalkanen said.


Quick facts: Faron Pharmaceuticals Ltd

Price: 232.5 GBX

Market: AIM
Market Cap: £100.65 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...



A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

2 min read